The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage
Abstract Background Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) represents a novel therapeutic approach for renal anemia, a prevalent complication of chronic kidney disease (CKD). However, the effects of HIF-PHI on renal functional outcomes remain poorly characterized. Here, the...
Saved in:
| Main Authors: | Jing Wang, Zuo-Lin Li, Yan Zhou, Zhong-Tang Li, Yan Tu, Xin-Hui Hu, Jin-Hua Zhu, Bi-Cheng Liu, Hong Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Cell Communication and Signaling |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12964-025-02175-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The importance of whey protein levels of Klotho and fibroblast growth of factor-23 (fgf-23) as early diagnostic markers of chronic kidney damage
by: L. Yu. Milovanova, et al.
Published: (2014-06-01) -
Phosphopenic form of osteomalacia in a patient with FGF23 producing tumor
by: A. S. Pushkareva, et al.
Published: (2022-05-01) -
Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01) -
Hypoxia Activates FGF-23-ERK/MAPK Signaling Pathway in Ischemia-Reperfusion-Induced Acute Kidney Injury
by: Weihua Liu, et al.
Published: (2024-10-01) -
Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01)